Concepedia

Publication | Open Access

4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study

DOIFull Paper Access

38

Citations

0

References

2025

Year

J.C-H. Yang, Yoon Jun Kim, SH Lee, B. Liu, Y.V. Ostapenko, Shun Lu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Pongwut Danchaivijitr,
Journal of Thoracic Oncology

No additional data available for this publication yet. Check back later!